Maitri Enterprises Ltd
Incorporated in 1991, Maitri Enterprises Ltd trades in Pharmaceutical & Medical Goods.[1]
- Market Cap ₹ 15.2 Cr.
- Current Price ₹ 34.6
- High / Low ₹ 44.7 / 18.7
- Stock P/E
- Book Value ₹ 10.0
- Dividend Yield 0.00 %
- ROCE 15.8 %
- ROE 20.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 148 to 68.9 days.
- Company's working capital requirements have reduced from 158 days to 51.6 days
Cons
- Stock is trading at 3.45 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 3.56% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 4.55 | 19.92 | 13.26 | 19.01 | 28.66 | 28.32 | |
| 4.47 | 19.23 | 12.76 | 18.76 | 26.48 | 27.75 | |
| Operating Profit | 0.08 | 0.69 | 0.50 | 0.25 | 2.18 | 0.57 |
| OPM % | 1.76% | 3.46% | 3.77% | 1.32% | 7.61% | 2.01% |
| 0.09 | 0.06 | 0.11 | 0.13 | -1.01 | -0.71 | |
| Interest | 0.02 | 0.32 | 0.37 | 0.73 | 0.77 | 0.70 |
| Depreciation | 0.05 | 0.09 | 0.07 | 0.06 | 0.07 | 0.08 |
| Profit before tax | 0.10 | 0.34 | 0.17 | -0.41 | 0.33 | -0.92 |
| Tax % | 40.00% | 32.35% | 94.12% | 9.76% | 48.48% | |
| 0.07 | 0.23 | 0.00 | -0.45 | 0.17 | -0.70 | |
| EPS in Rs | 0.37 | 0.52 | 0.00 | -1.02 | 0.39 | -1.60 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 61% |
| TTM: | -138% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 37% |
| 3 Years: | 6% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.40 | 4.40 | 4.40 | 4.40 | 4.40 |
| Reserves | 0.57 | 0.57 | 0.12 | 0.30 | 0.01 |
| 5.72 | 6.34 | 10.54 | 6.89 | 6.75 | |
| 6.85 | 7.09 | 6.61 | 4.77 | 3.70 | |
| Total Liabilities | 17.54 | 18.40 | 21.67 | 16.36 | 14.86 |
| 0.28 | 0.24 | 0.24 | 0.24 | 0.21 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.27 | 0.27 | 3.92 | 3.74 | 3.74 |
| 16.99 | 17.89 | 17.51 | 12.38 | 10.91 | |
| Total Assets | 17.54 | 18.40 | 21.67 | 16.36 | 14.86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -0.39 | 0.02 | 0.06 | 3.04 | ||
| -3.27 | -0.24 | -3.45 | 1.23 | ||
| 3.69 | 0.24 | 3.49 | -4.40 | ||
| Net Cash Flow | 0.03 | 0.02 | 0.10 | -0.12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 163.81 | 205.62 | 168.00 | 68.90 | |
| Inventory Days | 210.48 | 261.85 | 149.78 | 102.88 | |
| Days Payable | 186.79 | 206.97 | 122.59 | 78.10 | |
| Cash Conversion Cycle | 187.50 | 260.50 | 195.19 | 93.68 | |
| Working Capital Days | 157.40 | 247.74 | 176.07 | 51.58 | |
| ROCE % | 4.91% | 2.43% | 15.83% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Advertisement for an Un-Audited Standalone & Consolidated Financial Result of the Company for the Quarter and half year ended on September 30, 2025.
- Un-Audited Financial Results For The Quarter And Half Year Ended On 30.09.2025 14 Nov
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Nov - Approved Q2/H1 FY2025-26 results (Sep 30, 2025); director change; committee reconstitution.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
14 Nov - Approved Q2/H1 results (Sept 30, 2025); Independent Director resigned; Bharat Ramjibhai Sisodia appointed; committees reconstituted.
-
Reconstitution Of Committee
14 Nov - Approved Q2/H1 Sep 30, 2025 unaudited results; appointed Bharat Sisodia; Motwani resigned; committees reconstituted.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
MEL is engaged in trading of Pharmaceutical & Medical Goods in Gujarat. This includes sale of service by way of works contract. Apart from this, the co. is also in the business of Infra
structure and Real Estate.